Seroconversion post 1 dose | Seroconversion post 2 doses | T cell response | Modifying factors | |
---|---|---|---|---|
Solid organ cancer patients | 71% [24] | Use of steroids [24] | ||
Haematological malignancies | 50% [24] | Anti CD20 treatment [25] Stem cell transplant [25] BCMA targeted therapy [27] Anti CD38 regimens [27] Disease response [51] | ||
Healthy adults | 94% [28] | Age [28] |